Pair Name	Shogaol, Gefitinib
Disease Info	[ICD-11: 2C73]	Ovarian Cancer		Investigative
Biological Phenomena	Induction-->Endoplasmic reticulum stress
Gene Regulation	Up-regulation	Expression	ATF4	hsa468
	Up-regulation	Cleavage	CASP3	hsa836
	Up-regulation	Cleavage	CASP8	hsa841
	Up-regulation	Cleavage	CASP9	hsa842
	Up-regulation	Expression	CD63	hsa967
	Up-regulation	Expression	CDH1	hsa999
	Down-regulation	Expression	CDH2	hsa1000
	Up-regulation	Expression	DDIT3	hsa1649
	Up-regulation	Phosphorylation	EIF2AK3	hsa9451
	Up-regulation	Phosphorylation	EIF2S1	hsa1965
	Up-regulation	Expression	HSPA5	hsa3309
	Up-regulation	Expression	NOX4	hsa50507
	Down-regulation	Expression	SNAI1	hsa6615
	Down-regulation	Expression	SNAI2	hsa6591
	Up-regulation	Expression	TNFRSF10B	hsa8795
	Down-regulation	Expression	VIM	hsa7431
In Vitro Model	A2780	Ovarian endometrioid adenocarcinoma	Homo sapiens (Human)	CVCL_0134
	OVCAR-3	High grade ovarian serous adenocarcinoma	Homo sapiens (Human)	CVCL_0465
	Caov-3	High grade ovarian serous adenocarcinoma	Homo sapiens (Human)	CVCL_0201
	SK-OV-3	Ovarian serous cystadenocarcinoma	Homo sapiens (Human)	CVCL_0532
In Vivo Model	For the mice xenograft experiment, mice, aged six weeks, were inoculated with an A2780 human ovarian cancer cell line by subcutaneously (sc) implanting 1×10⁷ cultured cells into the right thigh.
Result	Our results suggest that 6-shogaol exerts a potential anti-cancer effect in ovarian cancer and combination treatment with 6-shogaol and gefitinib may provide a novel anti-tumor therapeutic strategy in gefitinib-resistant ovarian cancer.